Article Information
- November 13, 2020.
Article Versions
- Version 1 (August 4, 2020 - 11:24).
- You are viewing Version 2, the most recent version of this article.
Author Information
- Mohau S. Makatsa1,2,†,
- Marius B. Tincho1,2,†,
- Jerome M. Wendoh1,2,†,
- Sherazaan D. Ismail1,2,
- Rofhiwa Nesamari1,2,
- Francisco Pera3,
- Scott de Beer3,
- Anura David4,
- Sarika Jugwanth5,
- Maemu P. Gededzha5,
- Nakampe Mampeule5,
- Ian Sanne6,
- Wendy Stevens4,
- Lesley Scott4,
- Jonathan Blackburn1,7,
- Elizabeth S. Mayne5,
- Roanne S. Keeton1,2 and
- Wendy A. Burgers1,2,8,*
- 1Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
- 2Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa
- 3Cape Bio Pharms, Cape Town, South Africa
- 4Department of Molecular Medicine and Haematology, University of Witwatersrand, Johannesburg, South Africa
- 5Department of Immunology, Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory Service Johannesburg, South Africa
- 6Clinical HIV Research Unit, Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa
- 7Division of Chemical and Systems Biology, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa
- 8Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa
- ↵*Corresponding author:
Wendy Burgers, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa; Phone: +27-21-4066090; (wendy.burgers{at}uct.ac.za).
↵† M.S.M., M.B.T. and J.M.W. contributed equally to this work.
Author contributions: Conceived and designed the study and experiments: WAB, MSM, MBT, JMW, FP, SdB, ESM, LS and JB. Provided support and critical protocol review: WS, IS. Performed the experiments: MSM, MBT, JMW, AD, SJ, NM, MG, FP, SdB. Analyzed the data: MSM, AD, SJ, NM, MG, SDI, RN, RSK and WAB. Wrote the paper: FP, SDI, RN, RSK, MBT, JMW, MSM and WAB. All authors approved the final manuscript.
Contribution to the Field Statement The SARS-CoV-2 pandemic poses a significant global threat to lives and livelihoods, with over 16 million confirmed cases and at least 650 000 deaths from COVID-19 in the first 7 months of the pandemic. Developing tools to measure antibody responses and understand protective immunity to SARS-CoV-2 is a priority. Many expression systems exist to produce the proteins required in the establishment of these serological assays, but plant-based systems have several advantages over more widely used conventional protein expression systems. Most notably, they are rapid, scaleable and cost-effective, making them attractive protein expression systems particularly in low-income settings such as ours in Africa. We were able to develop a cost-effective serological assay by making use of plant-produced viral antigens. Our study demonstrates that recombinant SARS-CoV-2 proteins produced in plants enable the robust detection of SARS-CoV-2-specific antibodies equivalent to that observed in a high sensitivity commercial assay in which antigens were produced in a mammalian expression system. Our ELISA can be used to evaluate SARS-CoV-2 seroprevalence, describe the kinetics of the humoral immune response in infected individuals, and investigate humoral immunity in our setting where comorbidities are highly prevalent.
